# BRENTWOOD CAPITAL ADVISORS

The best deal. Done.

# HEALTHCARE TECHNOLOGY SECTOR UPDATE 2Q23

July 2023 www.brentwoodcapital.com

## **2Q23 Healthcare Technology Sector Overview**



### **BCA Market Commentary & Stock Indices Relative Performance**

- Q2 HCIT capital markets saw many of the same general trends persist from prior quarters: increased scrutiny around profitability, a bias for hard-dollar ROI in target companies, and a general apprehension about the course of the macro economy in light of the inflation/rates tension.
- Revenue cycle continued to see elevated activity due to its "have to have" support of reimbursement functions. In particular, there seems to be increased focus on companies providing technology-enablement to streamline and automate key functions (i.e., Alpha II) as well as companies supporting complex, hard-to-recover claims (FIRM RCM/Aspirion).
- Payers are also increasingly focused on cost containment solutions that can reduce unnecessary utilization while also providing care navigation capabilities for members (i.e., Vālenz Health).
- Anecdotally, sentiment seems to be more optimistic going into 2H 2023 as public markets continue to perform well, and markets slowly acclimate to an environment with higher rates. We anticipate a considerably more active second half as a pending back-log of deals begins to unwind.



| Select M&A and Financing Transactions |                       |                            |  |  |  |  |  |  |  |  |
|---------------------------------------|-----------------------|----------------------------|--|--|--|--|--|--|--|--|
| Date                                  | Target                | Acquiror(s)                | Target Business Description                              |  |  |  |  |  |  |  |
| 6/21/23                               | Vālenz                | Kelso Private Equity       | Provider of member navigation solutions                  |  |  |  |  |  |  |  |
| 6/13/23                               | Apixio                | New Mountain Capital       | Developer of AI healthcare technology platform           |  |  |  |  |  |  |  |
| 5/25/23                               | Alpha II              | TA Associates              | Provider of revenue cycle management technology          |  |  |  |  |  |  |  |
| 5/22/23                               | FIRM RCM              | Aspirion Health Resources  | Provider of revenue cycle management technology          |  |  |  |  |  |  |  |
| 5/16/23                               | MDPortals             | Reveleer                   | Developer of patient intelligence technology             |  |  |  |  |  |  |  |
| 5/09/23                               | Benefits Science      | MultiPlan                  | Developer of healthcare data analytics platform          |  |  |  |  |  |  |  |
| 4/27/23                               | Forward Advantage     | EXA Capital                | Provider of healthcare management solutions              |  |  |  |  |  |  |  |
| 4/25/23                               | Prodigo Solutions     | Global Healthcare Exchange | Developer of healthcare supply chain management platform |  |  |  |  |  |  |  |
| 4/13/23                               | ScanSTAT Technologies | Verisma Systems            | Provider of health information exchange solutions        |  |  |  |  |  |  |  |

| Select Public Trading Multiples  |        |             |                     |      |         |               |      |              |       |  |  |  |
|--|--------|-------------|---------------------|------|---------|---------------|------|--------------|-------|--|--|--|
| (\$M except share prices)  |        | Stock Price | <u>% of 52-Week</u> |      |         | TEV / Revenue |      | TEV / EBITDA |       |  |  |  |
| Company  | Ticker | 6/30/23     | High                | Low  | TEV     | LTM           | NTM  | LTM          | NTM   |  |  |  |
| CPSI   | CPSI   | \$24.69     | 72%                 | 112% | \$514   | 1.5x          | 1.5x | 9.5x         | 8.4x  |  |  |  |
| Definitive Healthcare  | DH     | \$11.00     | 37%                 | 126% | \$1,156 | 5.0x          | 4.4x | 19.1x        | 15.9x |  |  |  |
| Health Catalyst  | HCT    | \$12.50     | 68%                 | 195% | \$670   | 2.4x          | 2.2x | N/M          | N/M   |  |  |  |
| HealthEquity   | HQY    | \$63.14     | 80%                 | 129% | \$6,395 | 7.4x          | 6.5x | 24.0x        | 18.8x |  |  |  |
| Healthstream   | HSTM   | \$24.56     | 89%                 | 120% | \$725   | 2.7x          | 2.5x | 13.5x        | 12.0x |  |  |  |
| NextGen Healthcare   | NXGN   | \$16.22     | 74%                 | 106% | \$1,158 | 1.8x          | 1.6x | 10.3x        | 9.3x  |  |  |  |
| Phreesia   | PHR    | \$31.01     | 78%                 | 143% | \$1,706 | 5.7x          | 4.8x | N/M          | N/M   |  |  |  |
| Teladoc  | TDOC   | \$25.32     | 57%                 | 117% | \$5,204 | 2.1x          | 1.9x | 20.1x        | 16.8x |  |  |  |
| R1 RCM   | RCM    | \$18.45     | 68%                 | 275% | \$9,713 | 4.9x          | 4.0x | 17.4x        | 15.2x |  |  |  |
| Note: EBITDA includes add-backs for stock-based compensation and non-recurring |        |             |                     |      |         | 3.7x          | 3.3x | 16.3x        | 13.8x |  |  |  |
| expenses. Data per SEC filings and PitchBook.                                  |        |             |                     |      |         | 2.7x          | 2.5x | 17.4x        | 15.2x |  |  |  |

### **Brentwood Capital Advisors**

### **Industry Bankers**

John Kibler | Managing Director (312) 656-9296 jkibler@brentwoodcapital.com

Patrick Price | Director (615) 905-8023 pprice@brentwoodcapital.com **Porter Meadors** | *Managing Director* (615) 224-3821 pmeadors@brentwoodcapital.com

**Kyle Witty** | *Director* (804) 389-3042 kwitty@brentwoodcapital.com

### **Representative Transactions**





